CLIN CHEM LAB MED:多中心研究评估I型前胶原蛋白n末端前肽(PINP)检测方法的一致性

2019-11-17 MedSci MedSci原创

生物化学骨转换标志物(BTM)是在细胞水平上评估骨重建的主要工具。在研究中,I型前胶原蛋白(PINP)的n端前肽被推荐作为骨形成的参考标记。

生物化学骨转换标志物(BTM)是在细胞水平上评估骨重建的主要工具。在研究中,I型前胶原蛋白(PINP)n端前肽被推荐作为骨形成的参考标记。

本研究描述了一个多中心研究的结果,研究人员检测常规临床实验室检测血清和血浆中的PINP。从位于四个中心(雅典,希腊[GR],哥本哈根,丹麦[DK],列日,比利时[BE]和谢菲尔德,英国[英国])收集了到骨质疏松症诊所就诊的796名患者的血清和血浆(EDTA)样本。根据制造商的说明,用每一种可用的常规临床实验室方法对标本进行一式两份的分析。采用Passing-Bablok回归、Bland-Altman图、v型评价方法、血清和血浆标本间PINP值的一致性相关系数以及方法间的一致性相关系数来确定结果之间的一致性,同时采用广义线性模型识别可能影响两种方法之间关系的变量。

结果表明,EDTA血浆和血清均可用于PINP的检测。研究人员观察到Orion放射免疫测定法与PINP (Roche CobasIDS iSYS)自动化方法之间存在显著的比例偏差,但两者的结果非常相似。多变量模型并没有改善两种方法之间的良好相关性。

研究表明,通过应用校正系数或正确分配校准值,可以使PINP试验更加一致。这项工作将通过制造商和临床实验室专业人士之间的进一步合作继续改善。

原始出处:

Etienne CavalierRichard EastellA multicenter study to evaluate harmonization of assays for N-terminal propeptide of type I procollagen (PINP): a report from the IFCC-IOF Joint Committee for Bone Metabolism

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1906942, encodeId=a1da1906942c3, content=<a href='/topic/show?id=d91e1943441' target=_blank style='color:#2F92EE;'>#一致性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19434, encryptionId=d91e1943441, topicName=一致性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Sun Dec 22 11:19:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904001, encodeId=d64c190400130, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sat Jan 04 23:19:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909507, encodeId=d57c190950e1d, content=<a href='/topic/show?id=16c6430324c' target=_blank style='color:#2F92EE;'>#多中心研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43032, encryptionId=16c6430324c, topicName=多中心研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Wed Sep 16 09:19:00 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457112, encodeId=2cf4145e11268, content=<a href='/topic/show?id=b7e86254347' target=_blank style='color:#2F92EE;'>#检测方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62543, encryptionId=b7e86254347, topicName=检测方法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fe35841975, createdName=gracezdd, createdTime=Tue Nov 19 12:19:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485721, encodeId=1e911485e211b, content=<a href='/topic/show?id=8f0c840392a' target=_blank style='color:#2F92EE;'>#胶原蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84039, encryptionId=8f0c840392a, topicName=胶原蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11fc8038511, createdName=12498e5fm14(暂无昵称), createdTime=Tue Nov 19 12:19:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610132, encodeId=78c41610132cf, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 19 12:19:00 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
    2019-12-22 zhanfl
  2. [GetPortalCommentsPageByObjectIdResponse(id=1906942, encodeId=a1da1906942c3, content=<a href='/topic/show?id=d91e1943441' target=_blank style='color:#2F92EE;'>#一致性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19434, encryptionId=d91e1943441, topicName=一致性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Sun Dec 22 11:19:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904001, encodeId=d64c190400130, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sat Jan 04 23:19:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909507, encodeId=d57c190950e1d, content=<a href='/topic/show?id=16c6430324c' target=_blank style='color:#2F92EE;'>#多中心研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43032, encryptionId=16c6430324c, topicName=多中心研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Wed Sep 16 09:19:00 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457112, encodeId=2cf4145e11268, content=<a href='/topic/show?id=b7e86254347' target=_blank style='color:#2F92EE;'>#检测方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62543, encryptionId=b7e86254347, topicName=检测方法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fe35841975, createdName=gracezdd, createdTime=Tue Nov 19 12:19:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485721, encodeId=1e911485e211b, content=<a href='/topic/show?id=8f0c840392a' target=_blank style='color:#2F92EE;'>#胶原蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84039, encryptionId=8f0c840392a, topicName=胶原蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11fc8038511, createdName=12498e5fm14(暂无昵称), createdTime=Tue Nov 19 12:19:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610132, encodeId=78c41610132cf, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 19 12:19:00 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1906942, encodeId=a1da1906942c3, content=<a href='/topic/show?id=d91e1943441' target=_blank style='color:#2F92EE;'>#一致性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19434, encryptionId=d91e1943441, topicName=一致性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Sun Dec 22 11:19:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904001, encodeId=d64c190400130, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sat Jan 04 23:19:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909507, encodeId=d57c190950e1d, content=<a href='/topic/show?id=16c6430324c' target=_blank style='color:#2F92EE;'>#多中心研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43032, encryptionId=16c6430324c, topicName=多中心研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Wed Sep 16 09:19:00 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457112, encodeId=2cf4145e11268, content=<a href='/topic/show?id=b7e86254347' target=_blank style='color:#2F92EE;'>#检测方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62543, encryptionId=b7e86254347, topicName=检测方法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fe35841975, createdName=gracezdd, createdTime=Tue Nov 19 12:19:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485721, encodeId=1e911485e211b, content=<a href='/topic/show?id=8f0c840392a' target=_blank style='color:#2F92EE;'>#胶原蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84039, encryptionId=8f0c840392a, topicName=胶原蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11fc8038511, createdName=12498e5fm14(暂无昵称), createdTime=Tue Nov 19 12:19:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610132, encodeId=78c41610132cf, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 19 12:19:00 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1906942, encodeId=a1da1906942c3, content=<a href='/topic/show?id=d91e1943441' target=_blank style='color:#2F92EE;'>#一致性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19434, encryptionId=d91e1943441, topicName=一致性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Sun Dec 22 11:19:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904001, encodeId=d64c190400130, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sat Jan 04 23:19:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909507, encodeId=d57c190950e1d, content=<a href='/topic/show?id=16c6430324c' target=_blank style='color:#2F92EE;'>#多中心研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43032, encryptionId=16c6430324c, topicName=多中心研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Wed Sep 16 09:19:00 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457112, encodeId=2cf4145e11268, content=<a href='/topic/show?id=b7e86254347' target=_blank style='color:#2F92EE;'>#检测方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62543, encryptionId=b7e86254347, topicName=检测方法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fe35841975, createdName=gracezdd, createdTime=Tue Nov 19 12:19:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485721, encodeId=1e911485e211b, content=<a href='/topic/show?id=8f0c840392a' target=_blank style='color:#2F92EE;'>#胶原蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84039, encryptionId=8f0c840392a, topicName=胶原蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11fc8038511, createdName=12498e5fm14(暂无昵称), createdTime=Tue Nov 19 12:19:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610132, encodeId=78c41610132cf, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 19 12:19:00 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1906942, encodeId=a1da1906942c3, content=<a href='/topic/show?id=d91e1943441' target=_blank style='color:#2F92EE;'>#一致性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19434, encryptionId=d91e1943441, topicName=一致性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Sun Dec 22 11:19:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904001, encodeId=d64c190400130, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sat Jan 04 23:19:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909507, encodeId=d57c190950e1d, content=<a href='/topic/show?id=16c6430324c' target=_blank style='color:#2F92EE;'>#多中心研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43032, encryptionId=16c6430324c, topicName=多中心研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Wed Sep 16 09:19:00 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457112, encodeId=2cf4145e11268, content=<a href='/topic/show?id=b7e86254347' target=_blank style='color:#2F92EE;'>#检测方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62543, encryptionId=b7e86254347, topicName=检测方法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fe35841975, createdName=gracezdd, createdTime=Tue Nov 19 12:19:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485721, encodeId=1e911485e211b, content=<a href='/topic/show?id=8f0c840392a' target=_blank style='color:#2F92EE;'>#胶原蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84039, encryptionId=8f0c840392a, topicName=胶原蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11fc8038511, createdName=12498e5fm14(暂无昵称), createdTime=Tue Nov 19 12:19:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610132, encodeId=78c41610132cf, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 19 12:19:00 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1906942, encodeId=a1da1906942c3, content=<a href='/topic/show?id=d91e1943441' target=_blank style='color:#2F92EE;'>#一致性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19434, encryptionId=d91e1943441, topicName=一致性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Sun Dec 22 11:19:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904001, encodeId=d64c190400130, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sat Jan 04 23:19:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909507, encodeId=d57c190950e1d, content=<a href='/topic/show?id=16c6430324c' target=_blank style='color:#2F92EE;'>#多中心研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43032, encryptionId=16c6430324c, topicName=多中心研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Wed Sep 16 09:19:00 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457112, encodeId=2cf4145e11268, content=<a href='/topic/show?id=b7e86254347' target=_blank style='color:#2F92EE;'>#检测方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62543, encryptionId=b7e86254347, topicName=检测方法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fe35841975, createdName=gracezdd, createdTime=Tue Nov 19 12:19:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485721, encodeId=1e911485e211b, content=<a href='/topic/show?id=8f0c840392a' target=_blank style='color:#2F92EE;'>#胶原蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84039, encryptionId=8f0c840392a, topicName=胶原蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11fc8038511, createdName=12498e5fm14(暂无昵称), createdTime=Tue Nov 19 12:19:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610132, encodeId=78c41610132cf, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 19 12:19:00 CST 2019, time=2019-11-19, status=1, ipAttribution=)]

相关资讯

肿瘤标志物 7 种检测方法大比拼

肿瘤具有高死亡率、高转移率和高复发率,是危害人类健康的重大疾病。诊断肿瘤的传统方法有病理组织活检、核磁共振成像(magnetic resonance imaging,MRI)、电子计算机断层扫描(computed tomography,CT)、B超、X线胸片、内镜检查等。这些检查对于肿瘤早期的检测效果十分有限,部分检测方法不仅价格昂贵,且会给患者带来痛苦。因此,在肿瘤早期阶段开展快速、有效的检测十

止咳药被曝硫超标,虽检测方法有争议,但硫磺熏蒸中药本该严禁!

这几天,“硫磺熏蒸贝母”成为热词,太极集团、通药集团、哈药集团、云南白药集团4家知名药企的5款止咳药被曝检出较高含量硫磺,其中一款是儿童用药。随后,涉事企业之一的太极集团重庆中药二厂有限公司反驳称,检测方法不当致结果存疑,其生产的橘红丸中硫含量经再次检测并未超量。 是否因为检验方法不当导致检验结果存疑,已成为了目前争议的焦点。对此,北京中医药大学中药学院刘洋教授指出,当双方对检验方法有争

呼吁加强监管 FDA要对实验室开发检测方法开刀?

随着医学技术的进步,人们对于疾病治疗的理念也在发生变化。从研究人员到患者逐渐都意识到了预防比治疗更加重要。因此,临床上对于疾病监测方法的需求也越来越大。但是由于目前临床上缺少商业化的监测方案,所以临床上患者尝尝求助于实验室开发的检测方法(lab-developed tests, LDTs)。不过,这类检测方法是否100%有效?FDA的调查报告打上了一个大大的问号! 在本周公布的调查报告中,F

Sci Rep:Xpert MTB/RIF试验检测泌尿系结核的多中心评估

男生殖系统结核(GUTB)在肺外结核病例中占比多达40%。因为GUTB与推迟就医相关,进而导致严重的后果。因此,GUTB的快速检测是非常必要的。最近,有研究人员评估了利用尿液样本的Xpert MTB/RIF试验在快速检测泌尿系结核(UTB)和利福平抗性肺结核中的表现情况。研究总共包括了302名患者。研究人员对疑似UTB患者利用Xpert、涂片和MGIT 960培养进行了测试,并对阳性案例进行了药物

J Endod:外伤牙齿牙髓活力测试的诊断:一项系统性回顾

这篇系统性回顾的目的是为了评估活力测试(脉搏血氧测定法和流量测定)对于外伤牙齿牙髓的诊断效果,并与敏感性测试相比较。

Neurology:特发性快速眼动睡眠障碍的皮肤活检法

α-突触核蛋白的磷酸化皮肤活检对于特发性快速眼动睡眠障碍患者是一种安全敏感的检测方法